Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBarnett, Stephen Aen
dc.contributor.authorBaste, Jean-Marcen
dc.contributor.authorMurugappan, Kowsien
dc.contributor.authorTog, Checken
dc.contributor.authorBerlangieri, Salvatore Uen
dc.contributor.authorScott, Andrew Men
dc.contributor.authorSeevanayagam, Sivenen
dc.contributor.authorKnight, Simon Ren
dc.identifier.citationEuropean Journal of Cardio-thoracic Surgery : Official Journal of the European Association For Cardio-thoracic Surgery 2010; 39(1): 96-101en
dc.description.abstractPrognostic information known preoperatively allows stratification of patients to surgery; induction therapy and surgery; or definitive chemoradiotherapy and may prevent a futile thoracotomy. Attention has focussed on the standard uptake value (SUV) of the primary tumour but less has been described regarding the 18F-fluoro-2-deoxy-D-glucose (18F-FDG) avidity of mediastinal nodes. We aimed, in a group of surgically resected cN0-1 but pN2 tumours, to compare the survival of patients with and without 18F-FDG avid mediastinal nodes.Retrospective review of a surgical database identified cN0-1 non-small-cell lung cancer (NSCLC) patients with pN2 disease after resection. Survival of non-FDG avid N2 versus FDG avid N2 groups was compared after stratification according to variables found on univariate analysis to affect survival.From January 1993 to December 2006, 42 patients were identified; 27 (64%) had non-FDG avid N2 disease. Five-year and median survival were better in the non-FDG avid N2 disease group, 25% versus 0% and 30 (16-44) versus 13 (10-16) months, respectively (p=0.02). After 1998, the difference in survival was 41% versus 0% and 35 (14-56) versus 12 (16-18) months, respectively (p=0.02).After resection, patients with non-FDG avid N2 disease have better survival than patients with FDG avid N2 disease. Exploratory thoracotomy alone (after frozen section analysis) cannot be advocated in patients with non-FDG avid N2 disease as survival after resection appears at least equivalent to alternate therapeutic approaches in this group. This assertion may be tempered if right pneumonectomy is required or R0 resection is unachievable. Mediastinal nodal avidity may improve stratification in future studies of long-term survival in NSCLC.en
dc.subject.otherCarcinoma, Non-Small-Cell Lung.pathology.radionuclide imaging.secondary.surgeryen
dc.subject.otherEpidemiologic Methodsen
dc.subject.otherFluorodeoxyglucose F18.diagnostic useen
dc.subject.otherLung Neoplasms.pathology.radionuclide imaging.surgeryen
dc.subject.otherLymphatic Metastasisen
dc.subject.otherMiddle Ageden
dc.subject.otherNeoplasm Stagingen
dc.subject.otherPositron-Emission Tomography.methodsen
dc.subject.otherPostoperative Complicationsen
dc.subject.otherRadiopharmaceuticals.diagnostic useen
dc.subject.otherTreatment Outcomeen
dc.titleLong-term survival of 42 patients with resected N2 non-small-cell lung cancer: the impact of 2-(18)F-fluoro-2-deoxy-D-glucose positron emission tomogram mediastinal staging.en
dc.typeJournal Articleen
dc.identifier.journaltitleEuropean journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgeryen
dc.identifier.affiliationDepartment of Thoracic Surgery, Austin Health, Heidelberg, Victoria, Australiaen
dc.type.austinJournal Articleen, Stephen A
item.fulltextNo Fulltext-
item.openairetypeJournal Article- Surgery- Haematology- Newton-John Cancer Wellness and Research Centre- Imaging and Therapy- Newton-John Cancer Research Institute- Surgery-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Jun 22, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.